Arvinas, Inc. announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a member of the Executive Committee reporting to President and Chief Executive Officer John Houston, Ph.D. Effective March 18, 2024, Dr. Berkowitz will lead the ongoing clinical development of Arvinas? PROTAC protein degrader programs in oncology and neuroscience. Dr. Berkowitz has more than 20 years of experience in advancing programs through early and late stages of development, with proven ability in leading clinical development, regulatory, and medical affairs.

He has led multidisciplinary teams and has extensive knowledge of clinical trial design and execution. Dr. Berkowitz joins Arvinas from Bristol-Myers Squibb (BMS), where he was Senior Vice President, Development Unit Head, Hematology. While at BMS, Dr. Berkowitz?s teams achieved initial or subsequent global indications for Abecma, Breyanzi, Reblozyl, Onureg, and Inrebic, managed development life cycles for Revlimid, Pomalyst, and Sprycel, and initiated and/or designed registration trials for iberdomide, mezigdomide, and alnuctamab.

Prior to BMS, Dr. Berkowitz held roles of increasing responsibility in the areas of oncology, rare diseases, and hematology at Novartis, most recently as Vice President and Clinical Development Head for Hematology. Dr. Berkowitz earned his M.D. and Ph.D. from Columbia University and trained in medical oncology at the National Cancer Institute. The Company also announced that Ron Peck, M.D., who was Chief Medical Officer since joining Arvinas in mid-2019, will be leaving to pursue other opportunities.